VALITIC™ Featured by BuzzFeed for "Magical Results," Further Strengthening Consumer Brand Momentum
BuzzFeed Feature Expands VALITIC™'s Reach to BuzzFeed's Significantly Larger Consumer Audience
HERZLIYA, Israel and CALGARY, Alberta, Oct. 1, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ("Innocan" or the "Company"), through B.I. Sky Global Ltd., its consumer wellness subsidiary, is pleased to announce that VALITIC™ has been featured by BuzzFeed, which highlighted the product for its "magical results" on dark spots, acne scars and uneven tone.
BuzzFeed is a leading digital media and consumer commerce platform. In Q2 2026, BuzzFeed ranked #1 in total U.S. time spent among media brands in its competitive set, with 36.0 million hours, compared with 26.4 million hours for second-place People, according to Comscore data cited by BuzzFeed.*
The BuzzFeed feature provides VALITIC™ with exposure to BuzzFeed's broad consumer audience and supports the brand's continued expansion beyond its existing e-commerce channels. The recognition further strengthens VALITIC™'s position as a consumer-driven beauty brand and complements its growing presence across Amazon, its direct-to-consumer platform and expanding online retail channels.
Roni Kamhi, CEO of B.I. Sky Global and a COO of Innocan, commented:
"Being featured by a major consumer media platform such as BuzzFeed is an important milestone for VALITIC™. It reflects the brand's growing consumer recognition and creates an opportunity to reach new audiences in the competitive beauty market. We are leveraging VALITIC™'s strong digital presence to expand beyond Amazon, strengthen our direct-to-consumer platform and diversify our sales channels."
The Company believes these initiatives, together with growing consumer recognition and expanding digital visibility, provide a foundation for the continued development of VALITIC™ as a scalable consumer beauty brand.
*Source: Comscore data cited in BuzzFeed, Inc., "BuzzFeed, Inc. Reports Q2 2026 Financial Results" (August 4, 2026): https://ir.buzzfeed.com/news-releases/news-release-details/buzzfeed-inc-reports-q2-2026-financial-results
About Innocan:
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, B.I. Sky Global Ltd., which focuses on advanced, targeted online sales.
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 (516) 210-4025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, statements regarding the expected benefits of the BuzzFeed feature, the expansion of VALITIC™'s sales channels beyond Amazon, the growth of its direct-to-consumer platform and the continued development and growth of the VALITIC™ brand, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg
SOURCE Innocan Pharma Corporation
Share this article